company background image
MAGL

Magle Chemoswed Holding OM:MAGLE Stock Report

Last Price

kr23.80

Market Cap

kr257.0m

7D

8.2%

1Y

-35.7%

Updated

12 Aug, 2022

Data

Company Financials
MAGLE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance3/6
Financial Health5/6
Dividends0/6

MAGLE Stock Overview

Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacturing in the areas of pharmaceutical chemistry and pharmaceutical technology in Sweden.

Magle Chemoswed Holding AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Magle Chemoswed Holding
Historical stock prices
Current Share Pricekr23.80
52 Week Highkr42.00
52 Week Lowkr20.00
Beta1.16
1 Month Change12.26%
3 Month Change10.18%
1 Year Change-35.68%
3 Year Changen/a
5 Year Changen/a
Change since IPO16.04%

Recent News & Updates

Shareholder Returns

MAGLESE Life SciencesSE Market
7D8.2%5.8%2.3%
1Y-35.7%-52.0%-21.8%

Return vs Industry: MAGLE exceeded the Swedish Life Sciences industry which returned -51.8% over the past year.

Return vs Market: MAGLE underperformed the Swedish Market which returned -22.1% over the past year.

Price Volatility

Is MAGLE's price volatile compared to industry and market?
MAGLE volatility
MAGLE Average Weekly Movement6.3%
Life Sciences Industry Average Movement7.8%
Market Average Movement7.2%
10% most volatile stocks in SE Market12.7%
10% least volatile stocks in SE Market4.5%

Stable Share Price: MAGLE is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: MAGLE's weekly volatility has decreased from 12% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
194469Justin Piercehttps://www.maglechemoswed.com

Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacturing in the areas of pharmaceutical chemistry and pharmaceutical technology in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); and research, development, and production of products in the areas of wound care and diagnostics with a focus on products based on degradable starch microspheres. Its APIs include Warfarin sodium products that are used as anticoagulants for multiple indications; Melperone hydrochloride, which is an antipsychotic agent; Isradipine, a calcium channel blocker used to treat hypertension; Amantadine sulfate that is used in the treatment of central nervous system disorders; and Benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease.

Magle Chemoswed Holding AB (publ) Fundamentals Summary

How do Magle Chemoswed Holding's earnings and revenue compare to its market cap?
MAGLE fundamental statistics
Market Capkr257.04m
Earnings (TTM)kr4.19m
Revenue (TTM)kr132.15m

61.3x

P/E Ratio

1.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MAGLE income statement (TTM)
Revenuekr132.15m
Cost of Revenuekr21.31m
Gross Profitkr110.83m
Other Expenseskr106.64m
Earningskr4.19m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Aug 17, 2022

Earnings per share (EPS)0.39
Gross Margin83.87%
Net Profit Margin3.17%
Debt/Equity Ratio21.9%

How did MAGLE perform over the long term?

See historical performance and comparison